Novartis AG (NVS)
- Previous Close
120.42 - Open
120.37 - Bid 120.00 x 1100
- Ask 121.00 x 800
- Day's Range
120.06 - 120.92 - 52 Week Range
92.19 - 120.92 - Volume
902,626 - Avg. Volume
1,274,453 - Market Cap (intraday)
244.751B - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
24.77 - EPS (TTM)
4.88 - Earnings Date Oct 29, 2024
- Forward Dividend & Yield 3.78 (3.12%)
- Ex-Dividend Date Mar 7, 2024
- 1y Target Est
115.66
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
www.novartis.com76,057
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NVS
View MorePerformance Overview: NVS
Trailing total returns as of 9/2/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVS
View MoreValuation Measures
Market Cap
244.08B
Enterprise Value
264.64B
Trailing P/E
24.72
Forward P/E
16.58
PEG Ratio (5yr expected)
4.87
Price/Sales (ttm)
5.11
Price/Book (mrq)
5.86
Enterprise Value/Revenue
5.42
Enterprise Value/EBITDA
13.94
Financial Highlights
Profitability and Income Statement
Profit Margin
33.11%
Return on Assets (ttm)
8.86%
Return on Equity (ttm)
21.50%
Revenue (ttm)
48.86B
Net Income Avi to Common (ttm)
10.08B
Diluted EPS (ttm)
4.88
Balance Sheet and Cash Flow
Total Cash (mrq)
8.43B
Total Debt/Equity (mrq)
69.18%
Levered Free Cash Flow (ttm)
14.81B